Saturday, March 10, 2018 3:59:17 PM
Ardm had a inhaled insulin product in clinical studies. Novartis went in a partnership with them to help develop the product, After Novartis spent 42 million dollars and had the product in the final stages of phase III, Novartis dropped the product because Pfizer's brand inhaled insulin (which made it to market first) was deemed to cause lung cancer turning the public off to inhaled insulin products.
A good example going on now is CNAT and Novartis.
The point being if a company gets to a certain level (BICX) where it looks like their product will get thought the clinical trials (bicx102) and will have of a good chance to make it to market and that product has a big market (fighting opiate addition) big Pharma companies are willing to gamble 10's of millions for a piece of that 10's of billions market.
And if you listen to the conference call carefully BICX has a company that is looking to partner with them, now that they go to move forward ruling from the FDA.
CC 54:40 to 55:20 IMPORTANT TO LISTEN VERY CAREFULLY TO WHAT HE IS SAYING
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM